Gilteritinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 577 publications

XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.

XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.

Journal: The Journal of clinical investigation

Published: September 01, 2026

Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies.

Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies.

Journal: Current opinion in hematology

Published: August 13, 2026

Discovery of a highly selective FLT3-ITD inhibitor with potent antileukemic activity based on 4-(2-fluorophenoxy)pyridine scaffold.

Discovery of a highly selective FLT3-ITD inhibitor with potent antileukemic activity based on 4-(2-fluorophenoxy)pyridine scaffold.

Journal: European journal of medicinal chemistry

Published: July 28, 2026

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.

Journal: Journal of managed care & specialty pharmacy

Published: July 27, 2026

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.

Journal: EJHaem

Published: July 14, 2026

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant.

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant.

Journal: Leukemia & lymphoma

Published: July 07, 2026

Gilteritinib enhances the inhibitory effect of dabrafenib on anaplastic thyroid carcinoma cells by suppressing the AXL signaling pathway

Gilteritinib enhances the inhibitory effect of dabrafenib on anaplastic thyroid carcinoma cells by suppressing the AXL signaling pathway

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: July 06, 2026

SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation.

SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 05, 2026

Gilteritinib-Associated Hypertriglyceridemia During Acute Myeloid Leukemia Triplet Therapy in a 52-Year-Old Man: A Case Report.

Gilteritinib-Associated Hypertriglyceridemia During Acute Myeloid Leukemia Triplet Therapy in a 52-Year-Old Man: A Case Report.

Journal: Cureus

Published: June 27, 2026

Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia.

Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 22, 2026

Recent advances in the treatment of FLT3-mutated acute myeloid leukemia.

Recent advances in the treatment of FLT3-mutated acute myeloid leukemia.

Journal: Blood research

Published: June 07, 2026

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

Journal: Science advances

Published: May 15, 2026

Showing 1-12 of 577

Last Updated: 09/26/2026